Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma

Human Immunology

Volumn 65, Issue 8, 2004, Pages 794-802

  Chakraborty, Nitya G ^a   Chattopadhyay, Subhasis ^a   Mehrotra, Shikhar ^a   Chhabra, Arvind ^a   Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

antigen presenting cells; APC; CTL; cytotoxic T lymphocytes; DC; dendritic cells; melanoma; PBL; PBMC; peripheral blood lymphocytes; peripheral blood mononuclear cells; T regulatory cells; T reg; TIL; tumor vaccine; tumor infiltrating lymphocytes

Indexed keywords

ALANYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLTHREONYLVALINE; DNA VACCINE; GLUTAMYLALANYLASPARTYLPROLYLTHREONYLGLYCYLHISTIDYLSERYLTYROSINE; HLA A1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA ANTIGEN 1; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL FRACTIONATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DILUTION; HUMAN; HUMAN TISSUE; IMMUNIZATION; MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STAINING; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; HLA-A ANTIGENS; HUMANS; INTERLEUKIN-10; ISOANTIGENS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 4444279152     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2004.05.012     Document Type: Article

References (34)

1. G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F.M. Marincola, A. Anichini Cancer immunotherapy with peptide-based vaccines what have we achieved? Where are we going? J Natl Cancer Inst 94 2002 805
2. B. Mukherji, N.G. Chakraborty, S. Yamasaki, T. Okino, H. Yamase, J.R. Sporn, S.K. Kurtzman, M.T. Ergin, J. Ozols, J. Meehan, F. Mauri Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells Proc Natl Acad Sci U S A 92 1995 8078
3. F.J. Hsu, C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, B. Taidi, E.G. Engleman, R. Levy Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat Med 2 1996 52
4. + T cell response to repetitive stimulation with antigen-presenting cells in vitro implications in designing antigen-presenting cell-based tumor vaccines J Immunol 162 1999 5576
5. R.J. North, A. Digiacomo, E.S. Dye Suppression of antitumor immunity W.D. Otter E.J. Ruitenberg Tumor immunology, mechanisms, diagnosis, therapy 1987 Elsevier Science Publishers Amsterdam
6. N.G. Chakraborty, D.R. Twardzik, M. Sivanandham, M.T. Ergin, K.E. Hellstrom, B. Mukherji Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response J Immunol 145 1990 2359
7. B. Mukherji, A. Guha, N.G. Chakraborty, M. Sivanandham, A.L. Nashed, J.R. Sporn, M.T. Ergin Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma J Exp Med 169 1989 1961
8. N.G. Chakraborty, J.R. Sporn, A.F. Tortora, S.H. Kurtzman, H. Yamase, M.T. Ergin, B. Mukherji Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma Cancer Immunol Immunother 47 1998 58
9. S. Yamasaki, T. Okino, N.G. Chakraborty, W.O. Adkisson, A. Sampieri, S.J. Padula, F. Mauri, B. Mukherji Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients Cancer Immunol Immunother 40 1995 268
10. S. Mehrotra, R. Stevens, R. Zengou, N.G. Chakraborty, L.H. Butterfield, J.S. Economou, D.I. Dorsky, B. Mukherji Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro Cancer Res 63 2003 5607
11. P. Klenerman, V. Cerundolo, P.R. Dunbar Tracking T cells with tetramers new tales from new tools Nat Rev Immunol 2 2002 263
12. P. Romero, P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, V. Cerundolo Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes J Exp Med 188 1998 1641
13. X. Hu, N.G. Chakraborty, J.R. Sporn, S.H. Kurtzman, M.T. Ergin, B. Mukherji Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine Cancer Res 56 1996 2479
14. + T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene Cancer Res 58 1998 5305
15. A. Chakraborty, L. Li, N.G. Chakraborty, B. Mukherji Stimulatory and inhibitory differentiation of human myeloid dendritic cells Clin Immunol 94 2000 88
16. N. Suciu-Foca, J.S. Manavalan, R. Cortesini Generation and function of antigen-specific suppressor and regulatory T cells Transpl Immunol 11 2003 235
17. E. Gilboa, S.K. Nair, H.K. Lyerly Immunotherapy of cancer with dendritic-cell-based vaccines Cancer Immunol Immunother 46 1998 82
18. S.A. Rosenberg, J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, M.R. Parkhurst, Y. Kawakami, C.A. Seipp, J.H. Einhorn, D.E. White Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 1998 321
19. L. Van Parijs, A.K. Abbas Homeostasis and self-tolerance in the immune system turning lymphocytes off Science 280 1998 243
20. R.H. Schwartz, D.L. Mueller, M.K. Jenkins, H. Quill T-cell clonal anergy Cold Spring Harb Symp Quant Biol 54 1989 605
21. D. Moskophidis, F. Lechner, H. Pircher, R.M. Zinkernagel Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells Nature 362 1993 758
22. P.S. Ohashi, S. Oehen, K. Buerki, H. Pircher, C.T. Ohashi, B. Odermatt, B. Malissen, R.M. Zinkernagel, H. Hengartner Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice Cell 65 1991 305
23. M.B. Oldstone, M. Nerenberg, P. Southern, J. Price, H. Lewicki Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model role of anti-self (virus) immune response Cell 65 1991 319
24. S. Strand, W.J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, P.R. Galle Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 2 1996 1361
25. T.R. Mosmann, S. Sad The expanding universe of T-cell subsets Th1, Th2 and more Immunol Today 17 1996 138
26. P. Scott, P. Natovitz, R.L. Coffman, E. Pearce, A. Sher Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens J Exp Med 168 1988 1675
27. D. Jankovic, A. Sher, G. Yap Th1/Th2 effector choice in parasitic infection decision making by committee Curr Opin Immunol 13 2001 403
28. N.G. Chakraborty, J.R. Sporn, D.R. Pasquale, M.T. Ergin, B. Mukherji Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes Clin Immunol Immunopathol 59 1991 407
29. L. Ding, E.M. Shevach IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function J Immunol 148 1992 3133
30. A. O'Garra Cytokines induce the development of functionally heterogeneous T helper cell subsets Immunity 8 1998 275
31. + regulatory T cell subsets J Leukoc Biol 74 2003 471
32. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta Cancer Res 2 2002 5267
33. + regulatory T cells and their ligands implications for immunotherapy Immunity 20 2004 107
34. D. Ridgway The first 1000 dendritic cell vaccinees Cancer Invest 21 2003 873